ID   PUR8_HUMAN              Reviewed;         484 AA.
AC   P30566; B0QY76; O75495; Q5TI34;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   30-MAY-2000, sequence version 2.
DT   15-FEB-2017, entry version 186.
DE   RecName: Full=Adenylosuccinate lyase {ECO:0000303|PubMed:8404037};
DE            Short=ADSL {ECO:0000303|PubMed:8404037};
DE            Short=ASL;
DE            EC=4.3.2.2 {ECO:0000269|PubMed:16973378, ECO:0000269|PubMed:22812634};
DE   AltName: Full=Adenylosuccinase {ECO:0000303|PubMed:9266401};
DE            Short=ASase;
GN   Name=ADSL; Synonyms=AMPS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=8404037;
RA   Fon E.A., Demczuk S., Delattre O., Thomas G., Rouleau G.A.;
RT   "Mapping of the human adenylosuccinate lyase (ADSL) gene to chromosome
RT   22q13.1-->q13.2.";
RL   Cytogenet. Cell Genet. 64:201-203(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, AND VARIANTS
RP   ADSLD VAL-3; HIS-114; GLN-190; CYS-194; ASN-268; HIS-426 AND ASN-430.
RC   TISSUE=Skeletal muscle;
RX   PubMed=10888601; DOI=10.1093/hmg/9.10.1501;
RA   Kmoch S., Hartmannova H., Stiburkova B., Krijt J., Zikanova M.,
RA   Sebesta I.;
RT   "Human adenylosuccinate lyase (ADSL), cloning and characterization of
RT   full-length cDNA and its isoform, gene structure and molecular basis
RT   for ADSL deficiency in six patients.";
RL   Hum. Mol. Genet. 9:1501-1513(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2-484 (ISOFORM 1), AND VARIANT ADSLD
RP   PRO-438.
RX   PubMed=1302001; DOI=10.1038/ng0492-59;
RA   Stone R.L., Aimi J., Barshop B.A., Jaeken J., van den Berghe G.,
RA   Zalkin H., Dixon J.E.;
RT   "A mutation in adenylosuccinate lyase associated with mental
RT   retardation and autistic features.";
RL   Nat. Genet. 1:59-63(1992).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-20 AND 235-245, CLEAVAGE OF INITIATOR
RP   METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RA   Bienvenut W.V., Ramsay A., Leung H.Y.;
RL   Submitted (JUN-2009) to UniProtKB.
RN   [9]
RP   CATALYTIC ACTIVITY, AND SUBUNIT.
RX   PubMed=16973378; DOI=10.1016/j.pep.2006.07.023;
RA   Lee P., Colman R.F.;
RT   "Expression, purification, and characterization of stable, recombinant
RT   human adenylosuccinate lyase.";
RL   Protein Expr. Purif. 51:227-234(2007).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-147 AND LYS-295, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-9 AND SER-15, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [15]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-415, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) IN COMPLEXES WITH SUBSTRATE;
RP   FUMARATE AND AMP.
RG   Structural genomics consortium (SGC);
RT   "Human adenylosuccinate lyase in complex with its substrate N6-(1,2-
RT   dicarboxyethyl)-AMP, and its products AMP and fumarate.";
RL   Submitted (SEP-2007) to the PDB data bank.
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF WILD-TYPE AND VARIANT ADSLD
RP   CYS-303, CATALYTIC ACTIVITY, CHARACTERIZATION OF VARIANT ADSLD
RP   CYS-303, ACTIVE SITE, ENZYME REGULATION, AND SUBUNIT.
RX   PubMed=22812634; DOI=10.1021/bi300796y;
RA   Ray S.P., Deaton M.K., Capodagli G.C., Calkins L.A., Sawle L.,
RA   Ghosh K., Patterson D., Pegan S.D.;
RT   "Structural and biochemical characterization of human adenylosuccinate
RT   lyase (ADSL) and the R303C ADSL deficiency-associated mutation.";
RL   Biochemistry 51:6701-6713(2012).
RN   [18]
RP   VARIANT ADSLD HIS-426.
RX   PubMed=9266401; DOI=10.1023/A:1005323512982;
RA   Maaswinkel-Mooij P.D., Laan L.A.E.M., Onkenhout W., Brouwer O.F.,
RA   Jaeken J., Poorthuis B.J.H.M.;
RT   "Adenylosuccinase deficiency presenting with epilepsy in early
RT   infancy.";
RL   J. Inherit. Metab. Dis. 20:606-607(1997).
RN   [19]
RP   VARIANTS ADSLD ALA-100 AND TYR-422.
RX   PubMed=9545543; DOI=10.1016/S0925-4439(97)00086-0;
RA   Verginelli D., Luckow B., Crifo C., Salerno C., Gross M.;
RT   "Identification of new mutations in the adenylosuccinate lyase gene
RT   associated with impaired enzyme activity in lymphocytes and red blood
RT   cells.";
RL   Biochim. Biophys. Acta 1406:81-84(1998).
RN   [20]
RP   VARIANTS ADSLD VAL-72; TRP-141; GLN-190; GLU-246; CYS-303; ARG-395 AND
RP   HIS-426.
RX   PubMed=10090474;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:3<197::AID-HUMU3>3.0.CO;2-D;
RA   Marie S., Cuppens H., Heuterspreute M., Jaspers M., Tola E.Z.,
RA   Gu X.X., Legius E., Vincent M.-F., Jaeken J., Cassiman J.-J.,
RA   van den Berghe G.;
RT   "Mutation analysis in adenylosuccinate lyase deficiency: eight novel
RT   mutations in the re-evaluated full ADSL coding sequence.";
RL   Hum. Mutat. 13:197-202(1999).
RN   [21]
RP   CHARACTERIZATION OF VARIANTS ADSLD VAL-2; LEU-26; TRP-141; CYS-303;
RP   ARG-395; HIS-426 AND SER-450.
RX   PubMed=10958654; DOI=10.1093/hmg/9.14.2159;
RA   Race V., Marie S., Vincent M.-F., Van den Berghe G.;
RT   "Clinical, biochemical and molecular genetic correlations in
RT   adenylosuccinate lyase deficiency.";
RL   Hum. Mol. Genet. 9:2159-2165(2000).
RN   [22]
RP   VARIANTS ADSLD VAL-311; MET-364; HIS-396 AND PRO-452.
RX   PubMed=12368987; DOI=10.1055/s-2002-34493;
RA   Castro M., Perez-Cerda C., Merinero B., Garcia M.J., Bernar J.,
RA   Gil Nagel A., Torres J., Bermudez M., Garavito P., Marie S.,
RA   Vincent F., Van den Berghe G., Ugarte M.;
RT   "Screening for adenylosuccinate lyase deficiency: clinical,
RT   biochemical and molecular findings in four patients.";
RL   Neuropediatrics 33:186-189(2002).
RN   [23]
RP   VARIANT ADSLD HIS-426.
RX   PubMed=12833398; DOI=10.1002/ajmg.a.20176;
RA   Edery P., Chabrier S., Ceballos-Picot I., Marie S., Vincent M.-F.,
RA   Tardieu M.;
RT   "Intrafamilial variability in the phenotypic expression of
RT   adenylosuccinate lyase deficiency: a report on three patients.";
RL   Am. J. Med. Genet. A 120:185-190(2003).
RN   [24]
RP   CHARACTERIZATION OF VARIANTS ADSLD CYS-194; GLU-246; VAL-311; CYS-396
RP   AND HIS-396, AND ENZYME REGULATION.
RX   PubMed=19405474; DOI=10.1021/bi802321m;
RA   Ariyananda Lde Z., Lee P., Antonopoulos C., Colman R.F.;
RT   "Biochemical and biophysical analysis of five disease-associated human
RT   adenylosuccinate lyase mutants.";
RL   Biochemistry 48:5291-5302(2009).
CC   -!- FUNCTION: Catalyzes two non-sequential steps in de novo AMP
CC       synthesis: converts (S)-2-(5-amino-1-(5-phospho-D-
CC       ribosyl)imidazole-4-carboxamido)succinate (SAICAR) to fumarate
CC       plus 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide, and
CC       thereby also contributes to de novo IMP synthesis, and converts
CC       succinyladenosine monophosphate (SAMP) to AMP and fumarate.
CC       {ECO:0000269|PubMed:10888601}.
CC   -!- CATALYTIC ACTIVITY: N(6)-(1,2-dicarboxyethyl)AMP = fumarate + AMP.
CC       {ECO:0000269|PubMed:16973378, ECO:0000269|PubMed:22812634}.
CC   -!- CATALYTIC ACTIVITY: (S)-2-(5-amino-1-(5-phospho-D-
CC       ribosyl)imidazole-4-carboxamido)succinate = fumarate + 5-amino-1-
CC       (5-phospho-D-ribosyl)imidazole-4-carboxamide.
CC       {ECO:0000269|PubMed:16973378, ECO:0000269|PubMed:22812634}.
CC   -!- ENZYME REGULATION: The enzyme reaction kinetics indicate
CC       cooperativity between subunits. {ECO:0000269|PubMed:19405474,
CC       ECO:0000269|PubMed:22812634}.
CC   -!- PATHWAY: Purine metabolism; AMP biosynthesis via de novo pathway;
CC       AMP from IMP: step 2/2.
CC   -!- PATHWAY: Purine metabolism; IMP biosynthesis via de novo pathway;
CC       5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide from 5-
CC       amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylate: step 2/2.
CC   -!- SUBUNIT: Homotetramer. Residues from neighboring subunits
CC       contribute catalytic and substrate-binding residues to each active
CC       site. {ECO:0000269|PubMed:16973378, ECO:0000269|PubMed:22812634}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P30566-1; Sequence=Displayed;
CC       Name=2; Synonyms=Delta-ADSL;
CC         IsoId=P30566-2; Sequence=VSP_000318;
CC         Note=Lacks enzymatic activity.;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. Both isoforms are
CC       produced by all tissues. Isoform 2 is 10-fold less abundant than
CC       isoform 1.
CC   -!- DISEASE: Adenylosuccinase deficiency (ADSLD) [MIM:103050]: An
CC       autosomal recessive disorder characterized by the accumulation in
CC       the body fluids of succinylaminoimidazole-carboxamide riboside
CC       (SAICA-riboside) and succinyladenosine (S-Ado). Most children
CC       display marked psychomotor delay, often accompanied by epilepsy or
CC       autistic features, or both, although some patients may be less
CC       profoundly retarded. Occasionally, growth retardation and muscular
CC       wasting are also present. {ECO:0000269|PubMed:10090474,
CC       ECO:0000269|PubMed:10888601, ECO:0000269|PubMed:10958654,
CC       ECO:0000269|PubMed:12368987, ECO:0000269|PubMed:12833398,
CC       ECO:0000269|PubMed:1302001, ECO:0000269|PubMed:19405474,
CC       ECO:0000269|PubMed:22812634, ECO:0000269|PubMed:9266401,
CC       ECO:0000269|PubMed:9545543}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the lyase 1 family. Adenylosuccinate lyase
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC60603.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=CAA46697.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=ADSLdb; Note=Adenylosuccinate lyase mutations
CC       database;
CC       URL="http://www.icp.ucl.ac.be/adsldb/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X65867; CAA46696.1; -; mRNA.
DR   EMBL; X65867; CAA46697.1; ALT_INIT; mRNA.
DR   EMBL; AF067853; AAC21560.1; -; mRNA.
DR   EMBL; AF067854; AAC21561.1; -; mRNA.
DR   EMBL; CR456368; CAG30254.1; -; mRNA.
DR   EMBL; AL022238; CAI18983.1; -; Genomic_DNA.
DR   EMBL; AL022238; CAQ08930.1; -; Genomic_DNA.
DR   EMBL; CH471095; EAW60375.1; -; Genomic_DNA.
DR   EMBL; BC000253; AAH00253.1; -; mRNA.
DR   EMBL; S60710; AAC60603.1; ALT_INIT; mRNA.
DR   CCDS; CCDS14001.1; -. [P30566-1]
DR   CCDS; CCDS46714.1; -. [P30566-2]
DR   RefSeq; NP_000017.1; NM_000026.3. [P30566-1]
DR   RefSeq; NP_001116850.1; NM_001123378.2. [P30566-2]
DR   RefSeq; NP_001304852.1; NM_001317923.1.
DR   UniGene; Hs.75527; -.
DR   PDB; 2J91; X-ray; 1.80 A; A/B/C/D=1-481.
DR   PDB; 2VD6; X-ray; 2.00 A; A/B/C/D=1-481.
DR   PDB; 4FFX; X-ray; 2.70 A; A/B/C/D=1-484.
DR   PDB; 4FLC; X-ray; 2.60 A; A/B/C/D=1-484.
DR   PDBsum; 2J91; -.
DR   PDBsum; 2VD6; -.
DR   PDBsum; 4FFX; -.
DR   PDBsum; 4FLC; -.
DR   ProteinModelPortal; P30566; -.
DR   SMR; P30566; -.
DR   BioGrid; 106667; 69.
DR   IntAct; P30566; 19.
DR   STRING; 9606.ENSP00000216194; -.
DR   iPTMnet; P30566; -.
DR   PhosphoSitePlus; P30566; -.
DR   SwissPalm; P30566; -.
DR   BioMuta; ADSL; -.
DR   DMDM; 6686318; -.
DR   EPD; P30566; -.
DR   PaxDb; P30566; -.
DR   PeptideAtlas; P30566; -.
DR   PRIDE; P30566; -.
DR   DNASU; 158; -.
DR   Ensembl; ENST00000342312; ENSP00000341429; ENSG00000239900. [P30566-2]
DR   Ensembl; ENST00000623063; ENSP00000485525; ENSG00000239900. [P30566-1]
DR   GeneID; 158; -.
DR   KEGG; hsa:158; -.
DR   UCSC; uc003ays.5; human. [P30566-1]
DR   CTD; 158; -.
DR   DisGeNET; 158; -.
DR   GeneCards; ADSL; -.
DR   HGNC; HGNC:291; ADSL.
DR   HPA; CAB019285; -.
DR   HPA; HPA000525; -.
DR   MalaCards; ADSL; -.
DR   MIM; 103050; phenotype.
DR   MIM; 608222; gene.
DR   neXtProt; NX_P30566; -.
DR   OpenTargets; ENSG00000239900; -.
DR   Orphanet; 46; Adenylosuccinate lyase deficiency.
DR   PharmGKB; PA24600; -.
DR   eggNOG; KOG2700; Eukaryota.
DR   eggNOG; COG0015; LUCA.
DR   GeneTree; ENSGT00390000013486; -.
DR   HOGENOM; HOG000033915; -.
DR   HOVERGEN; HBG000214; -.
DR   InParanoid; P30566; -.
DR   KO; K01756; -.
DR   PhylomeDB; P30566; -.
DR   TreeFam; TF106385; -.
DR   BioCyc; MetaCyc:HS02059-MONOMER; -.
DR   BRENDA; 4.3.2.2; 2681.
DR   Reactome; R-HSA-73817; Purine ribonucleoside monophosphate biosynthesis.
DR   SABIO-RK; P30566; -.
DR   UniPathway; UPA00074; UER00132.
DR   UniPathway; UPA00075; UER00336.
DR   EvolutionaryTrace; P30566; -.
DR   GeneWiki; Adenylosuccinate_lyase; -.
DR   GenomeRNAi; 158; -.
DR   PRO; PR:P30566; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000239900; -.
DR   CleanEx; HS_ADSL; -.
DR   ExpressionAtlas; P30566; baseline and differential.
DR   Genevisible; P30566; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0070626; F:(S)-2-(5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamido)succinate AMP-lyase (fumarate-forming) activity; IBA:GO_Central.
DR   GO; GO:0004018; F:N6-(1,2-dicarboxyethyl)AMP AMP-lyase (fumarate-forming) activity; IDA:UniProtKB.
DR   GO; GO:0044208; P:'de novo' AMP biosynthetic process; IBA:GO_Central.
DR   GO; GO:0006189; P:'de novo' IMP biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0009060; P:aerobic respiration; IEA:Ensembl.
DR   GO; GO:0006167; P:AMP biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0051262; P:protein tetramerization; IDA:UniProtKB.
DR   GO; GO:0006164; P:purine nucleotide biosynthetic process; IC:UniProtKB.
DR   GO; GO:0009168; P:purine ribonucleoside monophosphate biosynthetic process; TAS:Reactome.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0014850; P:response to muscle activity; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0042594; P:response to starvation; IEA:Ensembl.
DR   Gene3D; 1.10.275.10; -; 1.
DR   InterPro; IPR019468; AdenyloSucc_lyase_C.
DR   InterPro; IPR024083; Fumarase/histidase_N.
DR   InterPro; IPR020557; Fumarate_lyase_CS.
DR   InterPro; IPR000362; Fumarate_lyase_fam.
DR   InterPro; IPR022761; Fumarate_lyase_N.
DR   InterPro; IPR008948; L-Aspartase-like.
DR   InterPro; IPR004769; Pur_lyase.
DR   Pfam; PF10397; ADSL_C; 1.
DR   Pfam; PF00206; Lyase_1; 1.
DR   PRINTS; PR00149; FUMRATELYASE.
DR   SMART; SM00998; ADSL_C; 1.
DR   SUPFAM; SSF48557; SSF48557; 1.
DR   TIGRFAMs; TIGR00928; purB; 1.
DR   PROSITE; PS00163; FUMARATE_LYASES; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Epilepsy;
KW   Isopeptide bond; Lyase; Phosphoprotein; Purine biosynthesis;
KW   Reference proteome; Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000269|Ref.8}.
FT   CHAIN         2    484       Adenylosuccinate lyase.
FT                                /FTId=PRO_0000137892.
FT   REGION       20     21       Substrate binding; shared with
FT                                neighboring subunit.
FT   REGION       85     87       Substrate binding.
FT   REGION      111    112       Substrate binding.
FT   ACT_SITE    159    159       Proton donor/acceptor.
FT                                {ECO:0000269|PubMed:22812634}.
FT   ACT_SITE    289    289       Proton donor/acceptor.
FT                                {ECO:0000269|PubMed:22812634}.
FT   BINDING     241    241       Substrate.
FT   BINDING     303    303       Substrate; shared with neighboring
FT                                subunit.
FT   BINDING     329    329       Substrate.
FT   BINDING     334    334       Substrate.
FT   BINDING     338    338       Substrate.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000269|Ref.8}.
FT   MOD_RES       9      9       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      15     15       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     147    147       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     295    295       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   CROSSLNK    415    415       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT                                {ECO:0000244|PubMed:25114211}.
FT   VAR_SEQ     398    456       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:10888601,
FT                                ECO:0000303|PubMed:15461802}.
FT                                /FTId=VSP_000318.
FT   VARIANT       2      2       A -> V (in ADSLD; severe;
FT                                dbSNP:rs143083947).
FT                                {ECO:0000269|PubMed:10958654}.
FT                                /FTId=VAR_016930.
FT   VARIANT       3      3       A -> V (in ADSLD; severe).
FT                                {ECO:0000269|PubMed:10888601}.
FT                                /FTId=VAR_017078.
FT   VARIANT      26     26       M -> L (in ADSLD; severe).
FT                                {ECO:0000269|PubMed:10958654}.
FT                                /FTId=VAR_016931.
FT   VARIANT      31     31       S -> N (in dbSNP:rs5757921).
FT                                /FTId=VAR_037883.
FT   VARIANT      72     72       I -> V (in ADSLD; severe).
FT                                {ECO:0000269|PubMed:10090474}.
FT                                /FTId=VAR_007972.
FT   VARIANT     100    100       P -> A (in ADSLD; moderate;
FT                                dbSNP:rs119450942).
FT                                {ECO:0000269|PubMed:9545543}.
FT                                /FTId=VAR_017079.
FT   VARIANT     114    114       Y -> H (in ADSLD; severe; total loss of
FT                                activity; dbSNP:rs374259530).
FT                                {ECO:0000269|PubMed:10888601}.
FT                                /FTId=VAR_017080.
FT   VARIANT     141    141       R -> W (in ADSLD; severe;
FT                                dbSNP:rs756210458).
FT                                {ECO:0000269|PubMed:10090474,
FT                                ECO:0000269|PubMed:10958654}.
FT                                /FTId=VAR_007973.
FT   VARIANT     147    147       K -> M (in dbSNP:rs11089991).
FT                                /FTId=VAR_037884.
FT   VARIANT     190    190       R -> Q (in ADSLD; moderate;
FT                                dbSNP:rs28941471).
FT                                {ECO:0000269|PubMed:10090474,
FT                                ECO:0000269|PubMed:10888601}.
FT                                /FTId=VAR_007974.
FT   VARIANT     194    194       R -> C (in ADSLD; severe; reduces protein
FT                                stability). {ECO:0000269|PubMed:10888601,
FT                                ECO:0000269|PubMed:19405474}.
FT                                /FTId=VAR_017081.
FT   VARIANT     246    246       K -> E (in ADSLD; moderate; strongly
FT                                reduced catalytic activity;
FT                                dbSNP:rs119450944).
FT                                {ECO:0000269|PubMed:10090474,
FT                                ECO:0000269|PubMed:19405474}.
FT                                /FTId=VAR_007975.
FT   VARIANT     268    268       D -> N (in ADSLD; severe; total loss of
FT                                activity; dbSNP:rs746501563).
FT                                {ECO:0000269|PubMed:10888601}.
FT                                /FTId=VAR_017082.
FT   VARIANT     303    303       R -> C (in ADSLD; mild; strongly reduced
FT                                activity with SAMP, but only slightly
FT                                reduced activity with SAICAR; abolishes
FT                                cooperativity; dbSNP:rs373458753).
FT                                {ECO:0000269|PubMed:10090474,
FT                                ECO:0000269|PubMed:10958654,
FT                                ECO:0000269|PubMed:22812634}.
FT                                /FTId=VAR_007976.
FT   VARIANT     311    311       L -> V (in ADSLD; severe; slightly
FT                                reduced enzyme activity).
FT                                {ECO:0000269|PubMed:12368987,
FT                                ECO:0000269|PubMed:19405474}.
FT                                /FTId=VAR_017083.
FT   VARIANT     318    318       P -> L (in ADSLD; severe;
FT                                dbSNP:rs202064195).
FT                                /FTId=VAR_017084.
FT   VARIANT     364    364       V -> M (in ADSLD; severe;
FT                                dbSNP:rs370851726).
FT                                {ECO:0000269|PubMed:12368987}.
FT                                /FTId=VAR_017085.
FT   VARIANT     374    374       R -> W (in ADSLD; severe;
FT                                dbSNP:rs376533026).
FT                                /FTId=VAR_017086.
FT   VARIANT     395    395       S -> R (in ADSLD; severe).
FT                                {ECO:0000269|PubMed:10090474,
FT                                ECO:0000269|PubMed:10958654}.
FT                                /FTId=VAR_007977.
FT   VARIANT     396    396       R -> C (in ADSLD; severe; abolishes
FT                                cooperativity and reduces enzyme
FT                                activity; dbSNP:rs755492501).
FT                                {ECO:0000269|PubMed:19405474}.
FT                                /FTId=VAR_017087.
FT   VARIANT     396    396       R -> H (in ADSLD; severe; abolishes
FT                                cooperativity and reduces enzyme
FT                                activity; dbSNP:rs763542069).
FT                                {ECO:0000269|PubMed:12368987,
FT                                ECO:0000269|PubMed:19405474}.
FT                                /FTId=VAR_017088.
FT   VARIANT     422    422       D -> Y (in ADSLD; moderate;
FT                                dbSNP:rs119450943).
FT                                {ECO:0000269|PubMed:9545543}.
FT                                /FTId=VAR_017089.
FT   VARIANT     423    423       L -> V (in ADSLD; moderate).
FT                                /FTId=VAR_017090.
FT   VARIANT     426    426       R -> H (in ADSLD; severe; most frequent
FT                                mutation; dbSNP:rs119450941).
FT                                {ECO:0000269|PubMed:10090474,
FT                                ECO:0000269|PubMed:10888601,
FT                                ECO:0000269|PubMed:10958654,
FT                                ECO:0000269|PubMed:12833398,
FT                                ECO:0000269|PubMed:9266401}.
FT                                /FTId=VAR_007978.
FT   VARIANT     430    430       D -> N (in ADSLD; mild;
FT                                dbSNP:rs554254383).
FT                                {ECO:0000269|PubMed:10888601}.
FT                                /FTId=VAR_017091.
FT   VARIANT     438    438       S -> P (in ADSLD; severe;
FT                                dbSNP:rs119450940).
FT                                {ECO:0000269|PubMed:1302001}.
FT                                /FTId=VAR_000680.
FT   VARIANT     447    447       S -> P (in ADSLD; severe;
FT                                dbSNP:rs777821034).
FT                                /FTId=VAR_017092.
FT   VARIANT     450    450       T -> S (in ADSLD; moderate;
FT                                dbSNP:rs372895468).
FT                                {ECO:0000269|PubMed:10958654}.
FT                                /FTId=VAR_016932.
FT   VARIANT     452    452       R -> P (in ADSLD; severe).
FT                                {ECO:0000269|PubMed:12368987}.
FT                                /FTId=VAR_017093.
FT   HELIX        16     19       {ECO:0000244|PDB:2J91}.
FT   HELIX        24     29       {ECO:0000244|PDB:2J91}.
FT   HELIX        32     53       {ECO:0000244|PDB:2J91}.
FT   HELIX        59     66       {ECO:0000244|PDB:2J91}.
FT   STRAND       68     70       {ECO:0000244|PDB:4FFX}.
FT   HELIX        74     84       {ECO:0000244|PDB:2J91}.
FT   HELIX        87     98       {ECO:0000244|PDB:2J91}.
FT   TURN        100    102       {ECO:0000244|PDB:2J91}.
FT   HELIX       103    105       {ECO:0000244|PDB:2J91}.
FT   TURN        106    109       {ECO:0000244|PDB:2J91}.
FT   HELIX       113    148       {ECO:0000244|PDB:2J91}.
FT   TURN        149    151       {ECO:0000244|PDB:2J91}.
FT   STRAND      153    158       {ECO:0000244|PDB:2J91}.
FT   STRAND      161    167       {ECO:0000244|PDB:2J91}.
FT   HELIX       168    192       {ECO:0000244|PDB:2J91}.
FT   STRAND      201    204       {ECO:0000244|PDB:4FLC}.
FT   HELIX       206    211       {ECO:0000244|PDB:2J91}.
FT   TURN        212    214       {ECO:0000244|PDB:2J91}.
FT   HELIX       216    229       {ECO:0000244|PDB:2J91}.
FT   STRAND      240    242       {ECO:0000244|PDB:2J91}.
FT   HELIX       246    274       {ECO:0000244|PDB:2J91}.
FT   STRAND      277    279       {ECO:0000244|PDB:2J91}.
FT   HELIX       299    313       {ECO:0000244|PDB:2J91}.
FT   HELIX       316    323       {ECO:0000244|PDB:2J91}.
FT   HELIX       331    333       {ECO:0000244|PDB:2J91}.
FT   HELIX       334    360       {ECO:0000244|PDB:2J91}.
FT   HELIX       366    380       {ECO:0000244|PDB:2J91}.
FT   HELIX       382    389       {ECO:0000244|PDB:2J91}.
FT   TURN        391    393       {ECO:0000244|PDB:4FLC}.
FT   HELIX       396    416       {ECO:0000244|PDB:2J91}.
FT   HELIX       423    429       {ECO:0000244|PDB:2J91}.
FT   HELIX       431    433       {ECO:0000244|PDB:2J91}.
FT   HELIX       434    437       {ECO:0000244|PDB:2J91}.
FT   HELIX       440    443       {ECO:0000244|PDB:2J91}.
FT   HELIX       446    449       {ECO:0000244|PDB:2J91}.
FT   HELIX       453    463       {ECO:0000244|PDB:2J91}.
FT   HELIX       465    469       {ECO:0000244|PDB:2J91}.
FT   HELIX       470    472       {ECO:0000244|PDB:2J91}.
SQ   SEQUENCE   484 AA;  54889 MW;  7AA3A0A2C681FD94 CRC64;
     MAAGGDHGSP DSYRSPLASR YASPEMCFVF SDRYKFRTWR QLWLWLAEAE QTLGLPITDE
     QIQEMKSNLE NIDFKMAAEE EKRLRHDVMA HVHTFGHCCP KAAGIIHLGA TSCYVGDNTD
     LIILRNALDL LLPKLARVIS RLADFAKERA SLPTLGFTHF QPAQLTTVGK RCCLWIQDLC
     MDLQNLKRVR DDLRFRGVKG TTGTQASFLQ LFEGDDHKVE QLDKMVTEKA GFKRAFIITG
     QTYTRKVDIE VLSVLASLGA SVHKICTDIR LLANLKEMEE PFEKQQIGSS AMPYKRNPMR
     SERCCSLARH LMTLVMDPLQ TASVQWFERT LDDSANRRIC LAEAFLTADT ILNTLQNISE
     GLVVYPKVIE RRIRQELPFM ATENIIMAMV KAGGSRQDCH EKIRVLSQQA ASVVKQEGGD
     NDLIERIQVD AYFSPIHSQL DHLLDPSSFT GRASQQVQRF LEEEVYPLLK PYESVMKVKA
     ELCL
//
